Andre Moa

Recent Posts

How the coronavirus crisis could affect your new drug launch

Posted by Andre Moa on Apr 7, 2020 2:44:49 PM

 

The widespread disruption caused by the coronavirus pandemic is forcing pharmaceutical companies to think more creatively and flexibly about how their business model can accommodate new restraints such as home working, restricted face-to-face contact, travel bans, supply-chain bottlenecks, stalled clinical-trial recruitment, diverted healthcare budgets, closer scrutiny of drug reimbursement, and depleted staffing at regulatory agencies. Digital technology will be a crucial tool in addressing these challenges and softening the pandemic’s multiple potential impacts on drug launches.

Read More

Topics: Pharma launch planning, Pharma trends, Market access, launch readiness, Tender Management, #covid-19, coronavirus

From Volume to Value: Strategising launch readiness in 2020

Posted by Andre Moa on Feb 13, 2020 11:07:00 AM

 

One notable characteristic of the launch readiness landscape as we settle into 2020 is the lower volume of innovative drugs entering the marketplace. The record number of approvals granted in 2018 by the two most influential agencies, the US Food and Drug Administration and the European Medicines Agency, did not hold up in 2019.

Read More

Topics: Pharma launch planning, Pharma trends, Market access, launch readiness, Tender Management

5 Pharma Trends for 2020: Counting the value and cost of innovation

Posted by Andre Moa on Jan 16, 2020 12:48:01 PM

 

For all its reliance on innovation as a business driver, pharmaceuticals is a traditionally conservative industry that advances by small and careful steps. As we  map out some of the dominant pharma trends for 2020, perhaps we should also reflect on what ‘innovation’ actually means, what its value is, and what it costs.

Read More

Topics: Pharma launch planning, Pharma trends, Market access, launch readiness, Tender Management, #2019 Pharma Trends

2019 New Drug Approvals And Updates: The Year In Review

Posted by Andre Moa on Dec 6, 2019 12:24:26 PM

Launch excellence for pharmaceuticals depends on a multitude of factors, from pricing, reimbursement and health technology assessment (HTA) to positioning, sequencing, sales, marketing, media coverage and the competitive landscape. None of these can get off the ground, though, without regulatory approvals in key markets. Here, we tally up 2019 new drug approvals to date in the US and the European Union.

 

Read More

Topics: launch readiness

How digital transformation can streamline your new pharma product launch

Posted by Andre Moa on Nov 5, 2019 2:47:15 PM

Digital technology and media have disrupted and revolutionised pharmaceuticals from research to market entry and beyond. That presents some challenges to product launches but also opportunities to maximise launch efficiency. In an ever more global, complex and volatile market environment, digital transformation of a traditionally conservative industry creates fresh possibilities to bring both launch strategy and execution into alignment.  

Read More

Topics: launch readiness